Search

everythinglearnresearchcommunity

for

Search:↓

Applying the anti-cancer drug Bortezomib to skin can promote hair growth and increase hair proteins through the GATA-3 factor.

5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.

Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.

Testosterone reduces knee movement, while flutamide and finasteride increase it.

Special nanoparticles increased skin absorption of hair loss treatments with fewer side effects.

Tailored treatment is crucial for elderly men with BPH due to potential risks and benefits of medications.

Finasteride may help treat childhood brain tumors by activating certain genes.

Dutasteride, fesoterodine, and finasteride help older patients with urinary issues.

Health warnings and public health actions led to a significant drop in flutamide prescriptions for women, but off-label use still continues.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.

Finasteride may reduce prostate cancer risk.

Finasteride treats enlarged prostate and hair loss, but may cause side effects in some patients.

Combining baricitinib with UV-B therapy effectively treats non-segmental vitiligo and is well-tolerated.

Researchers created a new, efficient way to make Dutasteride, a hair loss and prostate drug, with high purity using a benzoyl group.

Finasteride effectively reduces prostate size in dogs with benign prostatic hyperplasia at a low, safe dose.

Finasteride is a cost-effective option for treating BPH, reducing risk of urinary issues and surgery.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

Bortezomib chemotherapy can cause temporary skin rashes.

Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.

UHP-sCESr is as effective as HESr for treating BPH symptoms.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

Reversed sequential therapy with cyproterone acetate was effective for treating women with hirsutism and related conditions.

Hexahydrobenzo[f]quinolines are effective at blocking the enzyme 5α-reductase.

Palbociclib generally maintains or improves quality of life in advanced breast cancer patients.

Finasteride reduces hair loss and treats BPH without major hormone changes, but may cause sexual dysfunction.

Bimatoprost can help treat hair loss.

The new compounds moderately block a specific enzyme and strongly counteract a male hormone, suggesting potential for treating certain male-related health conditions.